 I'm feeling great. I'm very active, back to work. In the meantime, I've had two grandbabies born, so I've been able to enjoy them very much. And I don't think I'd be here today if it wasn't for CAR T. CAR T therapy is really one of the most exciting new developments in cancer therapy in general and in cancer immunotherapy specifically. At the University of Maryland, Greenabown Comprehensive Cancer Center, we've treated over 70 patients with CAR T therapy, including patients with aggressive B cell lymphoma and patients with aggressive B cell leukemia. CAR T therapy can actually cure acute leukemia in children and young adults, and it can cure aggressive B cell lymphomas, which is the most common type of lymphoma. Each CAR T cell is capable of killing multiple B cell leukemia cells or B cell lymphoma cells. Some are referred to them as serial killers. Battle signs are stable. His eyes and nose is more than a meter positive. In CAR T cell therapy, we collect immune cells from a patient. These cells are then genetically modified and engineered to express a new protein, a totally synthetic protein on the cell surface called a CAR, which stands for chimeric antigen receptor, which is a freak of nature. It has an antibody on the outside and signaling T cell, signaling domains on the inside. This reprogrammed cell, after it's genetically engineered, modified, is grown up and cultured and then brought back to the patient and infused. Typically, patients who qualify for CAR T therapy have no other treatment options. When I heard the cancer word, I figured my days were numbered. To this day, I at times got to pinch myself to make sure that I am still in remission, but I got a lot of reasons to live and I was very happy with the result. Another aspect of our program is that it's very multifaceted. There is a strong commercial FDA approved therapy component. There is also a major research component where we're testing new CAR T therapies. This is a technology and a platform that will be applicable to many other types of cancers, including not just blood cancers, but also solid tumors like breast cancer and lung cancer and liver cancer. We also are working on ways to reduce some of the potential side effects of CAR T therapy to make it even safer and potentially be able to do it more in the outpatient setting, not just the inpatient setting, which is primarily where we do it now.